title: Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.
abstract: IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.
authors.affiliation: Berry Consultants, LLC, College Station, Texas, USA. scott@berryconsultants.com
authors.forename: Scott M
authors.initials: SM
authors.lastname: Berry
authors.forename: Kristine R
authors.initials: KR
authors.lastname: Broglio
authors.forename: Donald A
authors.initials: DA
authors.lastname: Berry
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001499:Bayes Theorem; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D006632:Histamine / Q000008:administration & dosage; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008390:Markov Chains; D008875:Middle Aged; D009010:Monte Carlo Method; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007376:Interleukin-2; D006632:Histamine